To assess the pneumococcal immune responses induced by 13vPnC when measured 1 month after the last scheduled dose of 13vPnC in each of 4 age groups To evaluate the acceptability of the safety profile of 13vPnC as measured by the incidence rates of local reactions, systemic events, and AEs. This objective is applicable to all 4 groups and both cohorts.